AFFIMED N.V. EO-,01/ NL0010872420 /
| 12/1/2023 8:00:23 AM | Chg. -0.0530 | Volume | Bid9:57:10 PM | Ask9:59:01 PM | High | Low |
|---|---|---|---|---|---|---|
| 0.4028EUR | -11.63% | 0 Turnover: 0.0000 |
-Bid Size: - | -Ask Size: - | 0.4028 | 0.4028 |
GlobeNewswire
3/24/2022
Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022
GlobeNewswire
3/8/2022
Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Rese...
GlobeNewswire
2/9/2022
Affimed Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK...
GlobeNewswire
1/6/2022
Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in ...
GlobeNewswire
12/13/2021
Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society...
GlobeNewswire
12/9/2021
Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients ...
GlobeNewswire
12/8/2021
Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combina...
GlobeNewswire
11/22/2021
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-deri...
GlobeNewswire
11/12/2021
Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC ...
GlobeNewswire
11/10/2021
Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
GlobeNewswire
11/8/2021
Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a ...
GlobeNewswire
11/4/2021
Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia
GlobeNewswire
11/4/2021
Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and...
GlobeNewswire
10/29/2021
Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021
GlobeNewswire
10/1/2021
Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at...
GlobeNewswire
9/8/2021
Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
GlobeNewswire
8/23/2021
Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021
GlobeNewswire
7/30/2021
Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potent...
GlobeNewswire
7/1/2021
Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress
GlobeNewswire
6/22/2021
Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021
GlobeNewswire
6/16/2021
Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board